Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
In January 2023, the 17th new patient was dosed with IMX-110 to date Positive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, Jan. […]